You are here: Industry Insights > SMA

News List

FDA accepts Novartis application for Zolgensma to treat SMA pharmaceutical-technology
December 04, 2018
The US Food and Drug Administration (FDA) has agreed to review a biologics licence application (BLA) by Novartis seeking approval for Zolgensma (AVXS-101) for treating spinal muscular atrophy (SMA) Type 1......
Novartis snaps up AveXis in $8.7bn deal pharmatimes
July 17, 2018
Novartis is buying US gene therapy group AveXis in a deal valued at $8.7 billion.
Roche ends development of olesoxime after "many difficulties" pharmatimes
July 12, 2018
Roche has ended development of its spinal muscular atrophy (SMA) drug olesoxime, citing "many difficulties".
PTC Therapeutics’ results in SMA has Biogen nervous pharmafile
June 22, 2018
Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that treatment is pretty central to the biotech’s portfolio, bringing in $364 million in revenue in the first quarter.
Roche resigns itself to failure on SMA drug pharmafile
June 07, 2018
Roche has announced that it will no longer seek to develop its treatment for spinal muscular atrophy (SMA), olesoxime, after encountering too many difficulties in bringing it through to patients.
Nusinersen enables infants with SMA to regain motor function europeanpharmaceuticalreview
November 03, 2017
Infants with SMA are more likely to show gains in motor function and survive without assisted support when treated with nusinersen…
Spotlight Enters into Research Agreement with Indiana University for SMA Therapies americanpharmaceuticalreview
August 17, 2017
Spotlight Innovation has entered into a Sponsored Research Agreement with Indiana University to support research directed by Elliot Androphy, M.D., aimed at developing drugs to treat patients with spinal muscular atrophy (SMA).
Cytokinetics receives FDA orphan drug status for Ck-2127107 to treat SMA pharmaceutical-technology
May 18, 2017
Biopharmaceutical company Cytokinetics’ CK-2127107has received orphan drug designation from the Office of Orphan Products Development of the US Food and Drug Administration (FDA) for the potential treatment of spinal muscular atrophy (SMA).

Previous page 1 2 3 4 5 6 Next page